Mike Evers, Author at ORTHOWORLD

Orthopedic Funding Slows, Focuses on Digital

While economic pressure slowed orthopedic funding in recent years, there is ample capital for enabling technology companies.

Feb 06, 2024

The company grew in the mid-teens for 2023 but can't fully go on offense until it resolves its supply chain issues.

Feb 02, 2024

The company's orthopedic sales grew nearly 10% in 2023, driven by strong procedure demand, leadership in robotics and momentum in trauma.

Feb 01, 2024

The company grew in the mid-single-digits in 2023 as new products and recovering markets fueled its rebound to pre-COVID levels.

Jan 24, 2024

Public orthopedic companies with over $2 billion in annual sales control more than 60% of the market, but face questions in 2024.

Jan 17, 2024

We expect around 30 orthopedic M&A transactions in 2024 with activity remaining focused on spine-related assets.

Jan 10, 2024

We expect another year of elevated growth rates, accelerating consolidation and economic stress for the orthopedic industry.

Jan 04, 2024

Orthopedic investors are prioritizing later-stage companies with a clear path to commercialization and profitability.

Dec 11, 2023

The orthopedic market will finish 2023 with significantly elevated growth rates compared to its historical norms.

Dec 11, 2023

Orthopedic M&A is more active and has higher multiples than general medtech, but economic conditions will limit growth for now.

Dec 05, 2023